Developing High-Quality Tools to Characterize Allograft Quality, Predict Transplant Outcomes and Expand Access to Kidney and Liver Transplantation
开发高质量工具来表征同种异体移植质量、预测移植结果并扩大肾移植和肝移植的机会
基本信息
- 批准号:10413907
- 负责人:
- 金额:$ 54.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:Acute Renal Failure with Renal Papillary NecrosisAllograftingBiliaryBiological MarkersBlood CirculationBlood PressureCalibrationCessation of lifeCharacteristicsClinicalClinical DataCommunitiesComplicationCreatinineDataDecision MakingDiscriminationElderlyEventFailureGrantHepatitisHospitalizationImpairmentIndividualIschemiaJointsKidneyKidney TransplantationKnowledgeLaboratoriesLifeLinkLiverMeasuresMedicareMethodologyMethodsModelingNamesOrganOrgan DonorOrgan SurvivalOrgan TransplantationOutcomeOutputOverdosePatientsPerfusionPharmaceutical PreparationsPolicy DevelopmentsPopulationProbabilityProvincePublic HealthRegistriesResearch PersonnelRiskRisk AssessmentSavingsSerumStatistical MethodsTechniquesTimeTransplantationUrineWaiting ListsWorkbasecomorbiditydemographicsgraft failurehemodynamicsimprovedindexingliver transplantationneglectnovelorgan allocationorgan injurypopulation healthpressuresecondary analysisstatisticstoolweb-based tool
项目摘要
Project Summary/Abstract
In the US, nearly 95,000 patients are waitlisted for a kidney transplant, yet in 2018, only 14,700 received a
deceased donor kidney transplant, while nearly 8,500 died or became too sick. The organ shortage is equally
intense for liver transplant; in 2018, among more than 14,000 waitlisted patients, only 7,700 received a
deceased donor liver transplant while 2,500 died or became too sick. Unfortunately, more than 5,000 kidneys
and 2,000 livers from deceased donors were offered for transplant in 2018, but never transplanted. Although a
subset of these organs was unsuitable for transplant, data clearly demonstrate that the inability to accurately
assess graft quality directly led to many discards and/or undermined our ability to guide organs to appropriate
patients. Prior to their organs being offered for transplant, deceased donors are hospitalized for days, often
with numerous longitudinal data points (e.g., laboratory values) available to assess organ function. Yet,
existing models of graft quality have these major flaws: 1) a reliance on cross-sectional clinical and laboratory
data directly prior to procurement; 2) neglect of biologically-relevant, longitudinal data from the donor terminal
hospitalization such serial hemodynamics (kidney and liver) and urine output (kidney); and 3) failure to
integrate interactions between donor and recipient characteristics. As a result, existing kidney and liver donor
risk models have inadequate prediction accuracy (C-statistics of only 0.6-0.65). Our group proposes to
advance the field by developing state-of-the art models that make use of extensive, longitudinal donor data
during the donor's terminal hospitalization—laboratory biomarkers of organ injury, and measures of organ
function and perfusion. Second, we will develop highly robust allograft risk models using the joint modeling
approach, which can account for longitudinal donor exposure data and time-to-event outcomes such as graft
failure, instead of standard techniques (e.g., Cox regression). Third, we will highlight the real-world impact of
the results in terms of population health. We have these specific aims: 1) Develop kidney graft failure models
using joint modeling to predict graft failure with higher discrimination and calibration relative to the current
kidney donor risk index; 2) Develop liver graft failure risk models using joint modeling to predict graft failure
with high discrimination and calibration; 3a) Simulate the change in allograft life years from better pairing
organs to recipients based on alignment of projected organ and patient survival; and 3b) Simulate the change
in the number of transplants and allograft life years for the transplant population by implementing improved
organ quality metrics in organ allocation to decrease discards. The models will be constructed using
comprehensive US transplant data and externally validated with data from two Canadian provinces. The grant
will also include important exploratory analyses of transplant complications by linking to data from Medicare.
We will finally develop a web-based tool to enable real-time predictions of organ outcomes to put the results in
the hands of clinicians and other investigators.
项目总结/摘要
在美国,近95,000名患者等待肾移植,但在2018年,只有14,700人接受了肾移植。
死亡捐赠者肾脏移植,而近8,500人死亡或病情严重。器官短缺同样
肝脏移植的激烈; 2018年,在14,000多名等待名单的患者中,只有7,700人接受了
2,500名死者捐赠者肝脏移植,而2,500人死亡或病情严重。不幸的是,超过5,000个肾脏
2018年,有2,000名已故捐赠者的肝脏被提供用于移植,但从未被移植。虽然
这些器官的子集不适合移植,数据清楚地表明,无法准确地
评估移植物质量直接导致了许多丢弃和/或破坏了我们引导器官进行适当移植的能力。
患者在他们的器官被提供用于移植之前,已故的捐赠者通常会住院几天,
具有多个纵向数据点(例如,实验室值),以评估器官功能。然而,
现有的移植物质量模型具有以下主要缺陷:1)依赖于横截面临床和实验室
直接在采购前的数据; 2)忽略来自供体终端的生物相关纵向数据
住院治疗,如连续血流动力学(肾脏和肝脏)和尿量(肾脏);以及3)未能
整合捐赠者和接受者特征之间的相互作用。因此,现有的肾脏和肝脏捐赠者
风险模型的预测准确性不足(C统计量仅为0.6-0.65)。我们小组建议
通过开发利用广泛的纵向供体数据的最先进模型来推进该领域
器官损伤的实验室生物标志物和器官损伤的测量
功能和灌注。其次,我们将使用关节建模开发高度稳健的同种异体移植风险模型
方法,可以解释纵向供体暴露数据和移植等事件发生时间结果
故障,而不是标准技术(例如,考克斯回归)。第三,我们将突出现实世界的影响,
在人口健康方面的结果。我们的具体目标是:1)建立移植肾衰竭模型
使用联合建模以相对于当前更高的区分度和校准来预测移植失败
肾供体风险指数; 2)使用联合建模开发肝移植失败风险模型以预测移植失败
具有高分辨力和校准; 3a)模拟同种异体移植物寿命年从更好配对的变化
基于投影器官和患者存活率的对准将器官移植到受体;以及3b)模拟变化
在移植数量和移植人口的同种异体移植生命年,
器官分配中的器官质量指标,以减少丢弃。模型将使用
全面的美国移植数据,并与来自加拿大两个省的数据进行外部验证。授出
还将通过与医疗保险数据的链接,包括对移植并发症的重要探索性分析。
我们最终将开发一种基于网络的工具,以实现对器官结果的实时预测,
临床医生和其他研究人员的手。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Seth Goldberg其他文献
Multivisceral transplantation utilizing hepatitis C virus–viremic donors for hepatitis C virus–negative recipients
利用丙型肝炎病毒阳性供体为丙型肝炎病毒阴性受者进行多器官联合移植
- DOI:
10.1016/j.ajt.2024.09.006 - 发表时间:
2025-01-01 - 期刊:
- 影响因子:8.200
- 作者:
Vanessa Addison;David Seth Goldberg;Rodrigo Vianna;Eric Martin;Jenn Garcia - 通讯作者:
Jenn Garcia
David Seth Goldberg的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Seth Goldberg', 18)}}的其他基金
3/4-The INTEGRATE Study: Evaluating INTEGRATEd Care to Improve Biopsychosocial Outcomes of Early Liver Transplantation for Alcohol-Associated Liver Disease
3/4-综合研究:评估综合护理以改善酒精相关性肝病早期肝移植的生物心理社会结果
- 批准号:
10710924 - 财政年份:2023
- 资助金额:
$ 54.62万 - 项目类别:
A trial of transplanting Hepatitis C-viremic kidneys into Hepatitis C-Negative kidney recipients (THINKER-NEXT)
将丙型肝炎病毒血症肾脏移植到丙型肝炎阴性肾脏接受者的试验(THINKER-NEXT)
- 批准号:
10605313 - 财政年份:2021
- 资助金额:
$ 54.62万 - 项目类别:
Evaluating the impact of genetic ancestry and HIV on cirrhosis progression and response to statin therapy among a diverse multi-ethnic cohort of patients with cirrhosis
评估遗传血统和 HIV 对不同多种族肝硬化患者的肝硬化进展和他汀类药物治疗反应的影响
- 批准号:
10491885 - 财政年份:2021
- 资助金额:
$ 54.62万 - 项目类别:
Evaluating the impact of genetic ancestry and HIV on cirrhosis progression and response to statin therapy among a diverse multi-ethnic cohort of patients with cirrhosis
评估遗传血统和 HIV 对不同多种族肝硬化患者的肝硬化进展和他汀类药物治疗反应的影响
- 批准号:
10700141 - 财政年份:2021
- 资助金额:
$ 54.62万 - 项目类别:
Evaluating the impact of genetic ancestry and HIV on cirrhosis progression and response to statin therapy among a diverse multi-ethnic cohort of patients with cirrhosis
评估遗传血统和 HIV 对不同多种族肝硬化患者的肝硬化进展和他汀类药物治疗反应的影响
- 批准号:
10310739 - 财政年份:2021
- 资助金额:
$ 54.62万 - 项目类别:
A trial of transplanting Hepatitis C-viremic kidneys into Hepatitis C-Negative kidney recipients (THINKER-NEXT)
将丙型肝炎病毒血症肾脏移植到丙型肝炎阴性肾脏接受者的试验(THINKER-NEXT)
- 批准号:
10095988 - 财政年份:2021
- 资助金额:
$ 54.62万 - 项目类别:
A trial of transplanting Hepatitis C-viremic kidneys into Hepatitis C-Negative kidney recipients (THINKER-NEXT)
将丙型肝炎病毒血症肾脏移植到丙型肝炎阴性肾脏接受者的试验(THINKER-NEXT)
- 批准号:
10392517 - 财政年份:2021
- 资助金额:
$ 54.62万 - 项目类别:
Developing High-Quality Tools to Characterize Allograft Quality, Predict Transplant Outcomes and Expand Access to Kidney and Liver Transplantation
开发高质量工具来表征同种异体移植质量、预测移植结果并扩大肾移植和肝移植的机会
- 批准号:
10201592 - 财政年份:2020
- 资助金额:
$ 54.62万 - 项目类别:
Developing High-Quality Tools to Characterize Allograft Quality, Predict Transplant Outcomes and Expand Access to Kidney and Liver Transplantation
开发高质量工具来表征同种异体移植质量、预测移植结果并扩大肾移植和肝移植的机会
- 批准号:
10605254 - 财政年份:2020
- 资助金额:
$ 54.62万 - 项目类别:
Using ethics, epidemiology and high-quality data to optimize the allocation of livers for transplantation
利用伦理学、流行病学和高质量数据来优化移植肝脏的分配
- 批准号:
10356830 - 财政年份:2019
- 资助金额:
$ 54.62万 - 项目类别:
相似海外基金
Establishment of novel osteochondral allografting combined with growth factor- collagen-binding domain fusion technology
新型同种异体骨软骨移植联合生长因子-胶原蛋白结合域融合技术的建立
- 批准号:
26462277 - 财政年份:2014
- 资助金额:
$ 54.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Translating PTH Therapy as an Adjuvant for Structural Allografting
将 PTH 疗法转化为结构性同种异体移植的佐剂
- 批准号:
8344380 - 财政年份:2012
- 资助金额:
$ 54.62万 - 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
- 批准号:
7878675 - 财政年份:2009
- 资助金额:
$ 54.62万 - 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
- 批准号:
7677758 - 财政年份:2009
- 资助金额:
$ 54.62万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
7466112 - 财政年份:2008
- 资助金额:
$ 54.62万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
8010394 - 财政年份:2008
- 资助金额:
$ 54.62万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
8208131 - 财政年份:2008
- 资助金额:
$ 54.62万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
7575273 - 财政年份:2008
- 资助金额:
$ 54.62万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
7765518 - 财政年份:2008
- 资助金额:
$ 54.62万 - 项目类别:














{{item.name}}会员




